A Clinical Research site network
Dedicated to Patient-Centic and Data-Driven Research
Welcome to Centex Studies
Centex Studies is a multi-specialty clinical research site network with five locations across Texas and Louisiana. Collectively our sites have conducted over 500 research studies, or clinical trials, on a wide variety of health conditions.
Providing the best care for our patients and the best data for our sponsors are our top priorities. Our experience, coupled with the most advanced research technology, is what ranks Centex Studies far above all other research sites.
Looking to get involved in research?
We are always looking for new PIs, Sub-Is, and referring physicians. Click here to find out how to get involved today!
Looking for diversity in your trial?
That, combined with our experience and technology, enables us to deliver the most accurate data in less time. Click here to learn more about our capabilities!
What Makes Centex Studies Different?
No one can do everything, but everyone can do something! If you're interested in learning more about our sites, our clinical trials, how to volunteer, or joining our physician referral network, email us today!
Become a VOLUNTEER
HELP US ADVANCE MEDICINE FOR FUTURE GENERATIONS!
Our Latest BlogView all
May 10, 2021 10:16:01 AM
It's Not The ENDO The World: Learn About Your Endometriosis Diagnosis
Ever been told by your doctor that you’re ovary-acting? Endometriosis is real, and so is the pain that comes along with it. In fact, Endometriosis is a prevalent gynecological condition in women. Read along to learn all about Endometriosis, symptoms, results of being left untreated, and...
In the NewsView all
Mar 16, 2021 4:13:28 PM
COVID-19 VACCINES FOR EXPECTING MOMS, CHILDREN, & TEENS AVAILABLE SOON
Research studies evaluating potential options will begin soon at Centex Studies – Houston
February 9, 2021 HOUSTON, TX – Wanting to protect expecting mothers and our children is only natural, but without the proper research, we have no way of knowing what is safe and what isn’t. So far, no...